Andrew Oxtoby - 10 Apr 2025 Form 4 Insider Report for Kalaris Therapeutics, Inc. (KLRS)

Role
President and Chief Executive Officer, Director
Signature
/s/ Andrew Oxtoby
Issuer symbol
KLRS
Transactions as of
10 Apr 2025
Net transactions value
$0
Form type
4
Filing time
11 Apr 2025, 16:55:49 UTC
Previous filing
18 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KLRS Stock Option (Right to Buy) Award $0 +287,000 $0.000000 287,000 10 Apr 2025 Common Stock 287,000 $7.31 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 18, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

Remarks:

President and Chief Executive Officer